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Abstract. As a future trend of healthcare, personalized medicine tailors med-
ical treatments to individual patients. It requires to identify a subset of pa-
tients with the best response to treatment. The subset can be defined by a
biomarker (e.g. expression of a gene) and its cutoff value. Topics on subset
identification have received massive attention. There are over 2 million hits
by keyword searches on Google Scholar. However, how to properly incorpo-
rate the identified subsets/biomarkers to design clinical trials is not trivial and
rarely discussed in the literature, which leads to a gap between research results
and real-world drug development.
To fill in this gap, we formulate the problem of clinical trial design into an
optimization problem involving high-dimensional integration, and propose a
novel computational solution based on Monte-Carlo and smoothing methods.
Our method utilizes the modern techniques of General-Purpose computing on
Graphics Processing Units for large-scale parallel computing. Compared to
the standard method in three-dimensional problems, our approach is more
accurate and 133 times faster. This advantage increases when dimensionality
increases. Our method is scalable to higher-dimensional problems since the
precision bound is a finite number not affected by dimensionality.
Our software will be available on GitHub and CRAN, which can be applied
to guide the design of clinical trials to incorporate the biomarker better. Al-
though our research is motivated by the design of clinical trials, the method can
be used widely to solve other optimization problems involving high-dimensional
integration.
Keywords: Personalized medicine, Biomarker, Design of Clinical Trials, Op-
timization with High-Dimensional Integration, GPU Computing, Monte Carlo,
Smoothing
1. Introduction
Personalized medicine is the future trend of healthcare, which tailors medical
treatments to individual patients. When treatments are given to the correct sub-
set of patients who have positive responses, patients can receive the most suitable
treatment according to their personal characteristics, and pharmaceutical compa-
nies can increase the chance of success in their clinical trials. The subset of patients
who respond to a drug is usually defined by a predictive biomarker (e.g. expression
level of a gene or a protein) and its threshold value. Biomarkers are typically molec-
ular (e.g. expression level of a gene) related to increased benefit (or toxicity) from
a particular drug [3]. For example, when HER2 expression level exceeds a thresh-
old (i.e. over-expressed), patients respond well to multiple cancer drugs, including
Trastuzumab [5]. Clinical trials with patient selection based on the expression level
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of HER2 typically show a positive effect in approximately 20% of metastatic breast
cancer patients [5, 17]. Similarly, the Pembrolizumab is a new immune-oncology
drug, which is only prescribed to cancer patients with high PD-L1 levels [7]. On the
other hand, here is an example of failed drug development due to its ignorance of
predictive biomarkers. In 2003, the US Food & Drug Administration (FDA) gave
accelerated approval to Gefitinib for lung cancer patients who failed with platinum-
based chemotherapy. This approval allows the drug to be sold to patients before
its Phase III trial, but its formal approval still requests upon a successful Phase III
trial. However, in 2005, FDA withdrew the approval because of lack of evidence
of drug efficacy in the subsequent Phase III trial. The post-trial analysis found
that only patients with gain-of-function mutations in the ATP-binding domain of
the receptor respond to Gefitinib [13]. In 2015, the FDA granted final approval
Gefitinib to patients with EFGR gene mutations as the biomarker. In summary,
using biomarkers to select subpopulations for clinical trials not only can increase
the chance of success but also decrease the costs (time and money) in drug de-
velopment. More importantly, we can save lives by forcing non-responders to use
alternative treatments.
In the community of clinical and biology research, ‘subset identification’ received
massive attention. As of May 01, 2020, there are about 2, 140, 000 hits by searching
this keyword on Google Scholar. However, there is a gap between the research of
subset/biomarker identification and its application in real-world drug development.
To fill in this gap, we need to pay extra attention as it is challenging to incorporate
the identified subsets/biomarkers into the design of Phase III clinical trials. In
drug development, Phase III clinical trials are the most important trials, since
their purposes are to confirm the drug efficacy and also get approval to the market
from regulatory agencies (e.g. FDA). The challenge of using subsets in real-world
drug development is that, before conducting Phase III studies, we hardly ever have
enough data to confirm the correctness of identified subsets or biomarkers. Hence,
it is hard to decide whether or not to use them in trial design, because there is a
considerable risk associated with either decision. On the other hand, it is also not
practical to use the post-trial data to confirm the subsets or biomarkers, because
regulatory agencies can not directly accept the post-study-identified biomarkers or
subsets. FDA requests an additional Phase III trial to confirm the results, which
leads to a substantial financial loss of multi-million dollars and the delay of multiple
years in highly competitive competitions of drug development. Such significant
losses are not acceptable for most companies.
Before conducting Phase III trials, most often, we know a potential predictive
biomarker (e.g. the expression level of a gene or a protein) but need to figure out
its threshold value to identify the subset. Trying multiple threshold values of a
biomarker leads to considering drug efficacy in multiple subsets of patients and
the entire population. At the design stage, we can seldom know which subset (or
entire population) is the true responder set. The current standard approach of the
pharmaceutical industry is to migrate the risks by testing drug efficacy both on the
entire population and all candidate subsets. When multiple tests are conducted in a
single clinical trial, regulatory agencies require controlling the Family-Wised Error
Rates (FWER) defined as the probability of false positive in any of the conducted
tests. To control FWER, Freidlin et al. [6] and Jiang et al. [11] proposed designs
for alpha-allocation, which enforce the sum of the p-value thresholds of all tests
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being equal to 0.05. As a generalization of Bonferroni correction, Alpha-allocation
keeps the assumption that all tests are independent. However, these tests are not
independent since they are conducted on the ‘nested’ populations. Therefore, an
adjusted method is proposed in Chen et al. [2] to incorporate such dependency. And
it allows controlling FWER level at 0.05, while the sum of all p-value thresholds
exceeds 0.05. The authors formulated the problem of the clinical trial design into
a constrained optimization problem, which maximizes the study power with the
constraint of controlling FWER no more than 0.05. They provided a computational
solution to find the best p-value thresholds for the tests on two nested populations
(‘one’ subset and the entire population). They proposed the optimization problem
for two-subset (i.e. three nested population) design problem, but did not provide
a computational solution and application examples. In real-world applications, the
major challenge in multi-subsets design is the heavy computation load in solving
such optimization problems involving higher dimensional integrations. Chen et al.
[4] provided a computationally feasible strategy to solve multi-subsets clinical design
problems. However, this approach over-simplified the optimization problem by
ignoring uncertainty in the design parameters (i.e. replacing the prior distributions
by fixed values).
In this paper, we consider the more realistic optimization problems proposed in
Chen et al. [2] and propose a novel computational approach to find the optimal
solution for multi-subsets problems in a reasonable amount of time. To solve the
optimization problems with high-dimensional integrations, we use on the Monte-
Carlo and smoothing methods. Due to the popularity of deep learning, the software
and hardware support in General-Purpose computing using Graphics Processing
Units (GPU) have exploded recently. We design our algorithm to be compatible
with GPU computing, which is 133 times faster than a standard algorithm using
CPU to solve optimization problems of three nested populations. The effect of
speed boost increases when dimensionality increases. Our method is also scalable
to higher-dimensional problems since the precision bound is a finite number, which
is not affected by dimensionality.
In the rest of the paper, in Section 2, we provide notations, introduce problems
and challenges in the design of multi-subpopulation clinical trials, and propose a
novel computational approach to the optimal design; in Section 3, we illustrate
the applications of our method to design multiple clinical trials and compare their
speed and precision with the optimal designs obtained by the standard algorithm.
Section 4 and 5 contain discussions and conclusions. We provide all mathematical
proofs and derivations in the Appendix.
2. Method
2.1. Notations and the Optimization Problem. In Phase III clinical trials, the
primary outcome is a time-to-event variable, such as overall survival or progression-
free survival in oncology trials. The drug efficacy in the study is tested based on
the fitted Cox regression model, specifically based on the Z-statistics defined by
the treatment effect on the drug versus placebo. Such tests are conducted on
the patients entire population and their multiple subsets simultaneously. We keep
the setting used in [2] and extend the problem to the higher dimensional spaces.
Therefore, we assume the potential predictive biomarker is a continuous variable
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(e.g. the expression level of a gene or a protein). A threshold value of this biomarker
is needed to distinguish responders and non-responders, but this value is unknown.
We assume (n − 1) different threshold values will be tested, which correspond
to (n − 1) nested sub-populations of patients. In the notation below, we order
the nested populations by their sample size from large to small. We denote the
i-th subpopulation contains ri proportion of patients in the entire population, for
i = 1, . . . , n and 1 = r1 > r2 > r3 > . . . > rn > 0. As defined in [2], the total
information units are denoted by I3, which is 25% of the total number of events
expected to be observed in the entire population, hence the information units for
the i-th subset are riI3. The value of I3 is decided by the sample size of the clinical
trial, and it is considered as fixed input in our optimization problem. We denote
X := (X1, X2, . . . , Xn) to be the Z-statistics of treatment effects in these n nested
populations.
We compare the Z-statistic Xi against the threshold value Z1−αi , which is the
1 − αi quantile of standard normal distribution. If the test is significant in any
population i ∈ {1, . . . , n}, the drug is considered as effective, and the largest ef-
fective subpopulation is defined as responders. The task of clinical trial design is
to decide the values of the significant levels α := (α1, α2, ..., αn), which maximize
study power and keep overall type I error ( i.e. FWER) under control.
Under the null hypothesis, the drug is not effective in any of these nested pop-
ulations, hence Xi ∼ N(0, 1) for all i’s. In Section A.1, we derive that the joint
distribution of these Z-statistics is a multivariate normal as
X1
X2
X3
...
Xn
 ∼ N

µ =

0
0
0
...
0
 ,Σ =

1
√
r2
√
r3 . . .
√
rn√
r2 1
√
r3
r2
. . .
√
rn
r2√
r3
√
r3
r2
1 . . .
√
rn
r3
...
...
...
. . .
...√
rn
√
rn
r2
√
rn
r3
... 1


(1)
We denote α0 as the desired upper bound of overall type I error, whose value is
often set as α0 = 0.05 for one-sided test or α0 = 0.025 for two-sided test. Since
the drug is considered as effective if it is significant in any tested populations, the
FWER should be the probability of making any false positive call in these n tests.
So the constraint of optimization is
(2) α0 = 1−P(Xi < Z1−αi , ∀i = 1, . . . , n| under H0) = 1−ΦΣ(Z1−α1 , Z1−α2 , ..., Z1−αn)
where ΦΣ() is the cumulative distribution function of the multivariate normal
distribution defined in Formula (1).
Under the alternative hypothesis, the drug is effective in at least one population.
To calculate the power, we need to specify the drug effect in each population.
We describe the drug effect using ∆ := (∆1,∆2, ..,∆n), where ∆i is the hazard
reduction of the survival model in the i-th population. As a trivial extension of
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[10, 2], the joint alternative distribution of (X1, X2, . . . , Xn) is

X1
X2
X3
...
Xn
 ∼ N

µ =

√
I3∆1√
r2I3∆2√
r3I3∆3
...√
rnI3∆n
 ,Σ =

1
√
r2
√
r3 . . .
√
rn√
r2 1
√
r3
r2
. . .
√
rn
r2√
r3
√
r3
r2
1 . . .
√
rn
r3
...
...
...
. . .
...√
rn
√
rn
r2
√
rn
r3
... 1


(3)
Investigating the actual effect size of study drug is always the primary goal of
clinical trials. Hence, the exact value of ∆i is always unknown at the design stage of
clinical trials. To incorporate the uncertainty of real effect size, we use the prior joint
distribution (instead of fixed values) of drug effect in all these nested populations
as an input parameter of study design, whose density function is denoted as f(∆).
Such prior knowledge of effect sizes ∆i’s are usually obtained from the analysis of
the results of early phase (i.e. Phase I or II) trials of the same drug or relevant
literature of similar studies.
The expected power with respect to the prior distribution of ∆ is given below
in Formula (4)
(4)
P (α) = E∆[1− P(Xi < Z1−αi , ∀i = 1 . . . , n| under H1)]
= 1−
∫
ΦΣ(Z1−α1 −
√
r1I3∆1, . . . , Z1−αn −
√
rnI3∆n)× f(∆)d∆
In summary, the optimal design problem of clinical trials is to find the best values
of the vector α which can be written as a constrained optimal problem below,
that maximizes the expected power P (α) defined in Formula (4) subjected to the
constraint of Formula (2),maximize(α1,...,αn) 1−
∫
ΦΣ(Z1−α1 −
√
r1I3∆1, . . . , Z1−αn −
√
rnI3∆n)× f(∆)d∆
subject to 1− ΦΣ(Z1−α1 , Z1−α2 , ..., Z1−αn) = α0
(5)
In this problem, (r1, .., rn) are fixed-value input parameters, whose values are
determined by the proportion relationship of nested subpopulations. The I3 is also
a fixed-value parameter whose value is determined by sample size of the entire
population. The prior distribution of expected drug effect f(∆) is learned from
early phase studies of the same drug or literature.
To solve problem (5), we first re-parametrize this n-dimensional constrained
problem into a n− 1 dimensional unconstrained problem by solving αn as a func-
tion of (α1, α2, .., αn−1) from equation (2). Then we apply the variant of the quasi-
Newton method of limited-memory Broyden–Fletcher–Goldfarb–Shanno algorithm
for bound-constrained optimization(L–BFGS–B) to find the solution. This algo-
rithm approximates the BFGS using a limited amount of computer memory [1, 19].
When n = 2, problem (5) is the same as in [2]. The extension of problem (5)
from two dimensional to high dimensional is not hard. The real challenge is how
to overcome the heavy computational load to find the solution for the optimization
problem involving higher dimensional integrations in every iteration of the quasi-
Newton method. Next, we will propose our novel computation algorithms to address
this challenge.
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2.2. Calculate the High-Dimensional Integration by Monte Carlo and
GPU Computing. Solving problem (5) requires to evaluate a large number of
expected power defined in Formula (4) for various levels of α. Evaluation of the ex-
pected power is computing a high-dimensional integration, which is time-consuming
and is the major computation challenge in solving our optimization problem. This
high dimensional integration can not be further reduced by analytic and closed-
form solution; hence it needs to be evaluated using a computational approach. The
standard approach approximates such integration by fine-grids sum. The integra-
tion region is subdivided and then the sum of the area of each small region is the
estimation of Formula (4). There are two concerns of using standard approach in
our problem. First, it is computationally impractical for high dimensional problems
due to the curse of dimensionality. For example, to approximate a four-dimensional
integration using only 1000 grids in each dimension of ∆i, we need to calculate 10
12
quantities and calculate their sum. Second, using hyper-rectangle or trapezoid to
approximate the area under curve in each small region may lead to systematic bias.
In some publications, a fixed number is multiplied to the approximation, and the
number is ad-hocly chosen, but the real bias is way more complex than that.
To address these two issues, we propose a better approximation algorithm based
on Monte Carlo and large-scale parallel computing using GPU as follow. The
precision of our method can be further improved by utilizing smoothing technique,
which will be discussed in the next subsection.
We randomly generate large number (N1) of samples of ∆
(k) := (∆
(k)
1 ,∆
(k)
2 , ...,∆
(k)
n ), for k =
1, ..., N1 from the prior distribution with density function f(∆), and then approx-
imate the expected power P (α) by
(6) Pˆ (α) ≈ 1− 1
N1
N1∑
k=1
ΦΣ(Z1−α1 −
√
r1I3∆
(k)
1 , . . . , Z1−αn −
√
rnI3∆
(k)
n )
Note the Formula (6) requires evaluating N1 functions ΦΣ()’s, which can be pro-
cessed in parallel. This type of large scale parallel computing is suitable for GPU
computing. The GPU computing allows parallel process tens of thousands of ‘sim-
ple’ jobs at a time, which is much more than that of CPU computing can handle
(e.g. Tesla V100 can handle 81,920 threads at most one time).
Although calculating the CDF of a multivariate normal distribution is an easy
task for CPU, it is not implemented in GPU. Hence we need to design our algorithm
by further decomposing each CDF computing task to smaller and handleable jobs
by GPU computing. Since CDF is a semidefinite integral, it can be approximated
as the sum of results of many simpler operations. We approximate this two-layer
integration (inner-layer of CDF evaluation and outer-layer of calculating power)
using a two-layer sampling algorithm utilizing GPU computing, as described below.
To evaluate the functions ΦΣ()’s, we generate a large number (N2) inner-layer
samples of vector x(l) := (x
(l)
1 , x
(l)
2 , .., x
(l)
n ), l = 1, ..., N2 from the multivariate nor-
mal distribution given by Formula (1). For each outer-layer sample vector ∆(k), we
approximate the CDF function ΦΣ() as
(7)
ΦΣ(Z1−α1 −
√
I3∆
(k)
1 , . . . , Z1−αn −
√
rnI3∆
(k)
n ) ≈
1
N2
N2∑
l=1
δ(x
(l)
j ≤ Z1−αj −
√
rjI3∆
(k)
j ,∀j ∈ {1, . . . , n})
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where δ() is an indicator function that takes value 1 or 0 according to inside ex-
pression being true or false, respectively.
From the results of Formulas (6) and (7), the expected power defined in For-
mula (4) can be approximated by
(8) Pˆ (α) = 1− 1
N1N2
N1∑
k=1
N2∑
l=1
δ(x
(l)
j ≤ Z1−αj −
√
rjI3∆
(k)
j ,∀j ∈ {1, . . . , n})
Formula (7) decomposites the evaluation of CDF into the sum of a lot of com-
parison operations, which is handleable by GPU. These N1 ×N2 comparison jobs
can be handled by GPU in parallel, and then the N1 sum operations can also be
done in parallel by GPU computing.
The sample size needed in the two-layer sampling can be determined by the
desired precision of the estimated power, i.e. the bound of Var(Pˆ (α)). In Appendix
A.2, we derive a bound of this variance, which is given as
Var(Pˆ (α)) ≤ 1
4N1N2
,(9)
For example, if we set N1 = 10240, N2 = 20480 in Monte Carlo, the precision of
estimated power can be bounded by Var(Pˆ (α)) ≤ 1.19× 10−9.
We summarize the procedures discussed in this subsection in Algorithm 1 and
Algorithm 2. The Algorithm1 is for calculating the expected power P (α). The
Algorithm 2 is for calculating the CDF’s ΦΣ(Z1−α1 −
√
r1I3∆
(k)
1 , . . . , Z1−αn −√
rnI3∆
(k)
n ), which is called inside Algorithm 1.
2.3. Improve Accuracy by Smoothing. To find the optimal value of α that
maximize the expected power, in each iteration of the Newton method, it requires
calculating not only power P (α) for a given value of α, but also its derivative
P ′(α) to decide the value of α in the next iteration. Since the derivatives can-
not be calculated analytically, we have to estimate then numerically in the quasi-
Newton method. The accuracy of numerical derivatives affects whether the al-
gorithm is searching the solution in the correct direction. However small bias in
estimated power P (α) can lead to large errors in estimated derivatives P ′(α),
which makes Newton algorithm hard to converge. To fix this problem, we pro-
pose to use a smoothing technique to improve accuracy. In Appendix A.3, we
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prove that P (α) is an (n-1)-variate infinitely differentiable function with respect
to (α1, α2, . . . , αn−1). Such smoothness property enables us to borrow informa-
tion from neighboring points on the surface, and hence remove noise and improve
accuracy.
We propose to evaluate Pˆ (α) at many (N3) different values of α using Algorithm
1, and then fit a smooth surface (denoted as P˜ (α)) to these N3 points using Thin
Plate Splines (TPS) [8, 14]. The TPS model is well known to be versatile to model
any shape of high dimensional smooth surface, and it is more efficient than other
functional bases like polynomial splines. We use the optimal solution on the fit-
ted surface P˜ (α) as approximate solution of our original optimization problem (5),
since this solution can be easily and reliably found using the Newton method for
three reasons. First, we can specify good initial point to largely reduce the num-
ber of Newton iterations needed to converge. Specifically, among the N3 points
on the fitted surface, we select the one with the largest value of P˜ (α) as initial
point. Second, for any value of α, we can quickly evaluate P˜ (α) on the fitted TPS
with ‘no’ error, hence the derivatives P˜ ′(α) can be precisely estimated with low
computational cost. Third, the TPS surface enables borrowing information among
neighbor points of Pˆ (α)’s to correct their errors via smoothing.
The N3 points of α values can be selected using the procedure as follows. For
two-sided test, we set α0 = 0.025, hence 0 < αi < 0.025 for i = 1, . . . , n − 1. The
solution of re-parametrized and unconstrained optimization problem should be in
the (n − 1)-dimensional hyper rectangular (0, 0.25)(n−1). We select the m(n−1)
points as grid spanned by equally spaced m points in every dimension. Then we
solve αn for each spanned grid point with the constraint function in Formula (2),
and identify the invalid grid points using αn /∈ [0, 0.025]. From the valid grid points
we randomly select N3 points of α. Based on our experiments, we suggest using
N3 = 2000 for 3-dimensional problems with n = 3, and using N3 = 4000 for 4-
dimensional problems with n = 4. But user can revise this setting according to
their needs.
2.4. Design the nested subpopulations. The discussion above assumes the
nested subpopulations are pre-selected, but selecting subpopulations is also an im-
portant task of clinical trial design. Selecting subpopulations of is an optimization
problem respect to parameters r, which could be optimized (together with α) in
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problem (5). In the design of clinical trials, both the p-value thresholds α and the
sizes of subpopulations r are controllable parameters. However, we deliberately
avoid optimizing r in problem (5) for the following reason. The choice of α is
a pure mathematics problem to maximize the study power, which is a common
task for designing all clinical trials. On the other hand, the r is related to not
only potential drug efficacy on final target subpopulation but also future revenue.
Whether selling the drug to a slightly larger patient population while scarifying
some efficacy involves business decisions, which can be affected by many factors,
such as the competitors in the market and the cost-revenue-ratio etc. Hence select-
ing r can be guided by different utility functions in the real-world design of clinical
trials. Our modeling strategy is to make selecting α as a blackbox component and
selecting r as a component need specific users input on utility functions, which
requires separate the two components in modeling.
For simplicity of discussion, we use the power as the utility function in the
rest of this paper to illustrate the method of selecting best values of r, but users
can change it to any other study-specific utility functions involving both power and
other factors. To identify the best values of r, we use the following procedure. First,
we specify many settings of values of r, calculate their corresponding optimal powers
solved from problem (5). Second, we fit TPS of optimal power as functions of r. At
last, we find optimal solution of r on the fitted TPS using the same procedure as
for the TPS P˜ (α) discussed in the last subsection. Note, the smoothing technique
can be applied for finding the optimal value of r, since it is easy to prove that the
function P (α) defined in Formula (4) is also an indefinite differentiable function of
r.
The complexity of our algorithm for selecting r is approximately equal to the
complexity of solving optimization problem (5) multiplied by the number of settings
of r used to fit TPS, since fitting TPS and finding optimal point on TPS surfaces
can be done very quickly. To fit the TPS of r with decent quality, we suggest using
at least a hundred of points for the three-nested-population problems, and increase
the number for higher dimensional problems. Such procedure requires solving many
optimization problems of (5), which makes speed boosting more desired.
Finally, the optimal design is defined by the optimal value of r = rˆ together
with optimal solution of α under the setting of rˆ.
3. Applications in Design of Clinical Trials
Using examples of clinical trial designs, we illustrate the strength of our algo-
rithm. To demonstrate the advantage of our algorithm, we compare our results
and speed with a traditional algorithm. In the traditional algorithm, we use the
Newton method with L-BFGS-B algorithm, but we approximate the integrations
by grid sums.
In these examples, we design a Phase III clinical trial with a potential biomarker
effect. The biomarker is a continuous variable, and it has an unknown threshold
value for distinguishing responder patients and nonresponders. We consider the
design with two candidate threshold values and three candidate threshold values,
which correspond to three nested populations and four nested-populations, respec-
tively. To design these trials, we need to solve optimization problems with 3 and
4 dimensional integrations. For input parameters, we use the same setting as de-
scribed in [2], but extend the structure in higher dimensional problems. We set the
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total number of events in the entire population of patients in Phase III estimated
by
(10) I3 =
(Z1−α + Z1−β)2
log(1−∆)2
where α and β denotes the type-I and type-II error rates, respectively, which are
usually set as α = 0.025 (5% false positive rate for two sided tests) and β = 0.1
(90% power), and ∆ stands for the hazard reduction of the entire population. In
the setting of no biomarker effect, we set the drug efficacy ∆ to be a constant 0.25.
Hence, the information unit estimation I3 is 127, indicating that the total number
of patients’ events is 508, which is typical for oncology clinical trials. In the setting
of continuous biomarker effect, we set the drug efficacy ∆ to be 0.2 in the entire
population. Hence, the information unit I3 is 211, and the total number of patients’
events is 844.
The prior distribution of effect sizes in these nested populations (∆1,∆2, ...,∆n)
(learned from Phase I and II) is assumed to follow a multivariate normal distribu-
tion, given by,
(11)
∆1
∆2
∆3
...
∆n
 ∼ N
µ =

θ1
θ2
θ3
...
θn
 ,Σ =

σ21
√
r2σ1σ2
√
r3σ1σ3 ...
√
rnσ1σn√
r2σ1σ2 σ
2
2
√
r3/r2σ2σ3 ...
√
rn/r2σ2σn√
r3σ1σ3
√
r3/r2σ2σ3 σ
2
3 ...
√
rn/r3σ3σn
...
...
...
. . .
...√
rnσ1σn
√
rn/r2σ2σn
√
rn/r3σ3σn ... σ
2
n


where θi = −log(1−∆0i ), ∆0i is the point estimate of hazard reduction for the i-th
population, and we set σi =
1√
80∗ri/4
to represent the fact that it is harder to get
a precise estimation in the literature for the smaller proportion subpopulation.
In the examples of clinical trial design, we need to compare our method with
the standard method. To run the standard method within reasonable computation
time, we only consider the situation of n = 3 nested populations. This leads to
consider the investigation of two threshold values of biomarker. Since the sizes of
subpopulations are controllable parameters in clinical trial design, we need to find
the optimal setting of r that provides the best optimal power. To fit the TPS power
surface of r, from the grid spanned points generated by equally spaced points in
(r2, r3) ∈ (0, 1)× (0, 1) with step size 0.05, we select all (171) valid pairs satisfying
1 = r1 > r2 > r3 > 0. Assuming that the drug efficacy is a linear function of
the subpopulation’s size, we consider three conditions of biomarker effects: (a) No
biomarker effect with drug efficacy as a constant value (∆01 = ∆
0
2 = ∆
0
3 = 0.25);
(b) Weak biomarker effect that is continuous as ∆0i = 0.3 − 0.1ri, which linearly
increase from 0.2 to 0.3 when r decreases from 1 to 0; and (c) Strong biomarker
effect that is continuous as ∆0i = 0.8 − 0.6ri, which linearly increases from 0.2 to
0.8 as r decreases from 1 to 0. In summary, this leads to investigating the design
of clinical trials under 171 × 3 = 513 different settings. In deriving the optimal
clinical designs, we use m = 50 equally spaced grids of every dimension of ∆i to
calculate integrations in the traditional grid sum method. For our novel algorithm,
we use N3 = 2000 random selected values of α to fit the TPS P˜ (α), while for
each of these N3 points, we calculate the integration using Monte Carlo setting of
N1 = 10240, N2 = 20480.
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Figure 1 shows the optimal designs in various settings of (r2, r3). The top row
shows the optimal α values, while the bottom row shows their corresponding op-
timal powers. From the bottom row, we can learn the optimal setting of (r2, r3)
which achieve the maximum power. The rotatable 3D plots of these subfigures are
available, whose link is given in Appendix A.4. We find two common patterns of
relationships among optimal values of α1, α2, and α3. First, when r2 increases to be
close to 1, α2 increases sharply to reach the value of α1. We find similar relationship
between the α3 and r3. We explain this phenomenon as follows: the subpopulations
become identical to the entire population when r2 and r3 approaching 1. Hence,
the three optimal α’s should become identical as well. Second, the sum α1 +α2 +α3
of our optimal design can be larger than the desired FWER threshold (0.025 for
two-sided tests), which is as expected. The alpha-splitting approaches assume all
tests are independents, and have to enforce α1 + α2 + α3 = 0.025. In contrast, we
assume the tests conducted in nested populations are related as modeled in For-
mula (1) and hence allow more powerful designs as α1 + α2 + α3 > 0.025 while
keeping FWER controlled at 0.025.
Figure 1(a) shows the results of no biomarker effect conditions. The best power
is 0.6847, which is achieved at the setting of (r1 = 1, r2 = r3 = 0 ). This suggests
only consider the entire population without subsets, which reduces our optimization
problem into one dimension. In this optimal r setting, the corresponding optimal
p-value thresholds are (α1 = 0.025, α2 = 0, α3 = 0). Then r2, r3 are not ap-
proaching 1 (i.e. subsets are not identical to the entire population), the optimal
α always allocates large α1 to the entire population, while α2 and α3 are nearly
equal to 0. This decision almost ignored all subsets, which is reasonable since the
drug efficacy is a constant and the entire population has a larger sample size than
the subsets. Figure 1(b) shows the results of weak biomarker effect conditions.
The largest optimal power is 0.783, achieved at (r1 = 1, r2 = 0.365, r3 = 0).
This suggests only consider one subpopulation instead of two, which reduces our
optimization problem into two dimensions. In this optimal r setting, the optimal
p-value thresholds are (α1 = 0.0163, α2 = 0.0107, α3 = 0). The subpopula-
tion comprises 36.5% patient population. Figure 1(c) shows the results of strong
biomarker effect conditions. The largest optimal power is 0.0.977, achieved at
(r1 = 1, r2 = 0.446, r3 = 0.168), which corresponds to the optimal p-value thresh-
olds (α1 = 0.00194, α2 = 0.0135, α3 = 0.0133). This suggests considering two
subpopulations, which comprise 44.6% and 16.8% patient population, respectively.
Note the stronger the biomarker effect, the larger range that drug efficacy can
change, and the more subsets suggested by our optimal design. Such a decision
trend agrees with our intuition.
Table 3 shows the summary of computation times needed to solve a single op-
timization problem using each method. This summary is based on all 513 opti-
mization problems solved for generating Figure 1. The speed of our novel method
(using Nvidia Tesla V100 GPU on Compute Canada server Beluga) is 133 times
faster than the traditional method (using the CPU on the same server). Without
the help of the GPU algorithm the speed Monte Carlo approach is only 3.2 times
faster than the standard grid sum approach, which illustrates the importance of
utilizing GPU computing. Note the standard method uses at most 13672 seconds
to solve a single optimization problem, which seems to be acceptable. However, in
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the application of clinical trial design, we always need to understand the relation-
ship of power to the settings of r2 and r3, which requires solving a large number of
optimization problems. Solving all optimization problems used to generate Figure 1
requires 4.5 hours to run our algorithm and over 600 hours to run the standard grid
sum algorithm. The time required could be much more if we consider the opti-
mization problems of more than 3 dimensions. Hence, the speed boost offered by
our algorithm is critical in real applications. We will discuss this in more detail in
Section 4.
To compare the difference of optimal α obtained from our method and standard
method, we calculate their relative difference defined as R(αi) =
(α
(s)
i −α(n)i )
(α
(s)
i +α
(n)
i )/2
for
i = 1, 2, 3. Where α
(s)
i and α
(n)
i denotes optimal solution of αi obtained by the
standard method and the novel method, respectively. Figure 2 shows the relative
difference for all alpha values estimated for the 513 optimization problems. Except
for no biomarker conditions, most relative differences are well bounded by ±5%.
The optimal α obtained from two methods are not only similar in magnitude, but
also statistically (with all non-significant p-values from pairwise Wilcoxon tests).
Figure 1. Three dimensional optimal design for (a) no biomarker
effect, (b) weak biomarker effect , and (c) strong biomarker effect.
The rotatable 3D plots of these subfigures are available, whose link
is given in Appendix A.4. Each column is generated from the solu-
tions of 171 optimization problems (5) using different settings of r2
and r3. The top row shows the optimal α values, and the bottom
row shows their corresponding optimal powers. The optimal set-
ting of r can be found on the peak of power surface in the bottom
row, which guide us to define the subsets of patients.
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In no biomarker effect conditions, the solutions of α2 and α3 are very close to 0.
Hence the relative difference should be interpreted differently. In solutions of our
method, most values of α3 are less than 6×10−6, hence relative difference bounded
by 2 (as shown in boxplot) means both methods suggest almost ignoring the smallest
subset. In addition, the Wilcoxon test p value for α3 is non-significant (p = 0.6).
The relative difference of α2 is always positive (as seen in Figure 2 ), and the relative
difference of α1 is always negative (not enough resolution to show in Figure 2
since the absolute value of optimal α1 is big). Such a strong trend indicates that,
compared with the standard method, our method consistently suggests spending
more α-allocation on the entire population. This a wise suggestion, since in no
biomarker condition, we should only test drug efficacy on the entire population to
achieve better power.
To compare the precision of estimated optimal power between our novel algo-
rithm and the standard algorithm, we need to compare them against the ‘gold
standard’. For each optimal setting of α values in the left hand side panel of Fig-
ure 1, we calculate the expected power using a fine-grid sum approach with m = 500
grid points for each dimension. The values calculated using fine grid sum approach
should be more precise than both standard and novel method discussed above, so we
use them as ‘gold standard’ in the precision comparison. We denote the estimated
power using the standard method, our novel method, and the fine grid ‘gold stan-
dard’, and denoted as Ps,Pn, and Pf , respectively. For each optimization problem
we solved for Figure 1, we calculate precision difference Q = |Ps −Pf | − |Pn −Pf |.
Positive value of statistics Q indicates the solution of the novel method is closer
to the truth. Figure 3 shows all 513 Q statistics obtained from the optimization
problems solved for generating Figure 1. There is only one Q statistic slightly below
the horizontal line of Q = 0, which indicates that our method consistently provides
more precise solutions than the traditional method. Wilcoxon test p-values cor-
responding to all three boxes/conditions are less than 2.2 ∗ 10−16. We also find
the performance difference between our method and the standard method is not
always similar for different kinds of optimization problems. For example, the weak
biomarker effect problems have much more difference than strong biomarker effect
problems.
4. Discussion
To generate Figure 1, we need to solve 513 optimization problems, which takes
over 600 hours to run the standard method, and 4.5 hours to run our novel method.
This illustrates the importance of speed-boosting in real-world applications. In
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Figure 2. Boxplot of relative differences between the two meth-
ods. The relative difference is defined as R(αi) =
(α
(s)
i −α(n)i )
(α(s)+α
(n)
i )/2
for
i = 1, 2, 3. Where α
(s)
i and α
(n)
i denotes optimal solution of αi ob-
tained by the standard method and the novel method, respectively.
Except for no biomarker effect conditions, the relative errors are
well bounded by the two vertical lines at ±5%, which means their
relative difference is small. In addition, the pairwise Wilcoxon test
shows no significant difference in two methods, except for α1 and
α2 in no biomarker effect conditions. Interpreting the results of
no biomarker conditions are more complicated and are discussed
in the main text of this paper.
higher dimensional design, we can speed up more significantly. Based on our lim-
ited amount of experiments in the situation of n = 4 nested populations (results not
shown), our method is over 3000 times faster than the standard method. The fol-
lowing are the details about expected speed-change in n = 4 dimensional problems.
Compared with n = 3 dimensional problems, the standard method need 70 times
more time to solve an optimization problem, because of the one more dimension
of sum with grid size m = 50 and other related calculations. In comparison, our
novel method is about 3 times slower because of the doubled value of N3 and other
related calculations. We use N3 = 4000 to fit 4-dimensional TPS of P˜ (α), since
higher dimensional surface needs more points to achieve a similar level of good fit.
We are not the first algorithm using GPU to evaluate integrals. For example,
VEGAS [18] is one of the most popular integration packages in Python. To improve
accuracy without much time consumption, the algorithms in VEGAS are combined
with an adaptive multi-channel sampling method [15]. BASES [16] is another popu-
lar algorithm. It deals with the integration of singular functions. Typical computer
clusters can take months to perform the computations that calculate high dimen-
sional integration, but GPU accelerated solutions can massively speed up these
computations [9, 12]. However, these methods are mostly developed for general
purpose integration. General methods are not efficiently designed to utilize prop-
erties of our specific problem, and some methods (such as ZMCIntegral[18]) cannot
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Figure 3. Boxplot of precision difference statistics Q, defined as
Q = |Ps −Pf | − |Pn −Pf |. The Pf , Pn and Ps denote the optimal
power obtained by ”gold standard”, novel, and standard method,
respectively. Positive Q values indicate that our method is more
accurate than the standard method. Each box in this figure is made
from the solutions of 171 optimization problems in a biomarker
effect condition. Almost all data points are above the horizontal
line of Q = 0, which shows that our novel method consistently
outperforms the standard method.
handle our complex integral functions in our problem. This motivated us to imple-
ment our integral functions. In addition, the most contribution of our method is
incorporating a smoothing technique to improve precision and solve the converging
issue of the Newton methods, which is not proposed in previous studies.
The bound of variance Formula (9) leads to many advantages of sampling-based
methods over the standard sum-of-grid-value method. First, because the upper
bound of estimation variance is a finite number regardless of dimensionality, our
method is scalable to obtain the solution of higher dimensional problems with rea-
sonable precision and reasonable time. In contrast, to keep the same precision level,
the complexity of the ‘sum of grid values approximation’ method increases expo-
nentially with dimension. Second, our method can reach any desired precision level
by increasing the number of samples (i.e. N1 and N2) accordingly, whereas the
sum-of-grid approach introduce a systematic error by approximating area under a
curve using trapezoid shape.
5. Conclusion
In this work, we proposed a novel computational solution for optimization prob-
lems involving high dimensional integration, and applied it to the design of clinical
trials. Our algorithm utilizes GPU parallel computing to accelerate computation
by Monte Carlo. It incorporates a smoothing technique to not only fix the con-
vergence issue in the Newton method but also improve the precision of estimates.
Using examples, we illustrated that our novel algorithm outperforms the standard
method in the real- world design of clinical trials. Our method not only boosts the
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computing speed to solve the design problem within a reasonable amount of time,
but also improves the accuracy of estimations. We implement our algorithm using
R language with Python functions called inside R. We will make our software avail-
able via GitHub and CRAN after the manuscriptis accepted, so thatall researchers
can use to design their clinical trials.
This research is motivated by the problem of the design of clinical trials. Our
software is developed to help the design of clinical trials. However, our method
ofusing Monte Carlo, GPU computing, and smoothing can solve other general op-
timization problems with high-dimensional integration.
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Appendix
A.1 Derivation of the Covariance Matrix of Normal Distribution in For-
mula (1). As discussed in [2], the correlation efficient of Z-statistics between entire
population X1 and the k-th subpopulation Xk is
cor(X1, Xk) =
√
rk, for k = 2, . . . , n
Consider any two (the k-th and the l-th) nested subpopulations for 2 ≤ k < l ≤ n.
The l-th subpopulation is a subset of the k-th subpopulation and the proportion is
rl
rk
. We treat Xk as the new ‘full’ population, so we have
cor(Xk, Xl) =
√
rl
rk
, for 2 ≤ k < l ≤ n
A.2 Derivation of the Upper bound of Variance for the Estimated Power.
Let
Pˆkl = δ(x
(l)
j ≤ Z1−αj −
√
rjI3∆
(k)
j ,∀j ∈ {1, . . . , n})
Then, we have, for k = 1, . . . , N1, l = 1, . . . , N2,
E(Pˆkl) = 1− p(α)
V (Pˆkl) = p(α)(1− p(α)) ≤ 1
4
From Formula (8), we obtain
V ar(Pˆ (α)) =
1
N21N
2
2
N1∑
k=1
N2∑
l=1
V ar(Pˆkl) ≤ 1
4N1N2
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A.3 Proof of the Smoothness property of P(α1, ..., αn−1). Without loss of
generality, we prove P (α) is a smooth (infinitely differentialble) function of α for
n = 1. From Formula (4), we have
P (α) = 1−
∫ ∞
−∞
ΦΣ(Z1−α −
√
r1I3∆1)× f(∆1)d∆1
Then,
dP (α)
dα
= −
∫ ∞
−∞
φΣ(Z1−α −
√
r1I3∆1)
dZ1−α
dα
f(∆1)d∆1
=
∫ ∞
−∞
φΣ(Z1−α −
√
r1I3∆1)
1
φΣ(Z1−α)
f(∆1)d∆1
where φΣ(·) is the density function of the stadard normal distribution. It is clear
that dP (α)dα is a continuous function of α for all 0 < α < 1. Similarly, we could
abtain the second, third and fourth derivation of P (α), which are all continous
functions of α. Thus, P (α) is a smooth function of α, for all 0 < α < 1.
A.4 The links of rotatable 3D plots corresponding to subfigures in Fig-
ure 1. No biomarker effect:
Fitted TPS Surface of the optimal power : http://www.math.uvic.ca/˜ xuekui/HDDesign/Figure1.2
Fitted TPS Surface of the optimalα : http://www.math.uvic.ca/˜ xuekui/HDDesign/Figure1.1
Weak biomarker effect:
Fitted TPS Surface of the optimal power : http://www.math.uvic.ca/˜ xuekui/HDDesign/Figure1.4
Fitted TPS Surface of the optimalα : http://www.math.uvic.ca/˜ xuekui/HDDesign/Figure1.3
Strong biomarker effect:
Fitted TPS Surface of the optimal power : http://www.math.uvic.ca/˜ xuekui/HDDesign/Figure1.6
Fitted TPS Surface of the optimalα : http://www.math.uvic.ca/˜ xuekui/HDDesign/Figure1.5
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